Related Experiment Video
Updated: Mar 27, 2026
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
New cardiovascular risk factors exist, but are they clinically useful?
1Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. tjwang@partners.org
Insights
New cardiovascular disease biomarkers show limited clinical utility for primary prevention. Traditional risk factors remain crucial for predicting heart disease, while advanced technologies may yield future prognostic tools.
Area of Science:
- Cardiology
- Biomarker Research
- Preventive Medicine
Background:
- Substantial interest exists in identifying novel cardiovascular disease (CVD) risk factors to enhance understanding of disease biology.
- Circulating biomarkers are frequently investigated as potential new risk factors for CVD.
- A debate surrounds the validity and clinical utility of emerging biomarkers.
Purpose of the Study:
- To assess the readiness of newer biomarkers for routine clinical use in primary CVD prevention.
- To evaluate the predictive performance of traditional CVD risk factors.
- To explore the potential of advanced technologies for future biomarker discovery.
Main Methods:
- Systematic review and critical assessment of existing evidence on newer biomarkers.
- Analysis of the predictive accuracy of established cardiovascular risk factors.
- Consideration of technological advancements in molecular profiling for biomarker discovery.
Main Results:
- Most novel biomarkers are not yet suitable for routine primary prevention of CVD.
- Traditional risk factors demonstrate robust performance in predicting future cardiovascular events.
- Inadequate management of classic risk factors contributes significantly to preventable CVD events.
Conclusions:
- Current novel biomarkers lack sufficient evidence for widespread clinical adoption in primary prevention.
- Continued focus on optimizing the control of traditional risk factors is essential for reducing CVD.
- Emerging technologies hold promise for discovering future biomarkers with mechanistic and prognostic value.
Abstract:
There is substantial interest in identifying new risk factors for cardiovascular disease, to improve our understanding of disease biology and to account for the cases of heart disease that cannot be explained by known risk factors. Investigation of putative risk factors frequently involves the study of circulating biomarkers. In recent years, a spirited debate has arisen regarding the validity and usefulness of these new measures. A careful assessment of the evidence suggests that most newer biomarkers are not ready for routine clinical use in the primary prevention setting. The good news is that traditional risk factors perform quite well with regard to the prediction of future cardiovascular risk. Inadequate recognition and control of the 'classic' risk factors continues to account for a large number of avoidable cardiovascular events. At the same time, new insights into disease mechanisms should lead to the development of novel preventive therapies, regardless of how well biomarkers themselves perform in risk stratification. Furthermore, state-of-the-art technologies that allow the profiling of large panels of genes, transcripts, proteins, or small molecules should facilitate the discovery of newer biomarkers capable of providing both mechanistic insight and true prognostic utility.
Related Concept Videos
01:30Coronary Artery Disease III: Clinical Manifestations
01:30Coronary Artery Disease I: Introduction
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...